USD 46
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| QGEN | 0.2 | 2.1 | 4.4 | 7.0 | 10.1 | -0.1 | -5.0 | 29.0 | 87.5 | 2235.0 |
| S&P 500 | 1.0 | 3.7 | 2.1 | 2.3 | 8.2 | 25.4 | 31.0 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | QGEN |
| name | Qiagen N.V. |
| price | 46 |
| changes percentage | 0.2179 |
| change | 0.1 |
| day low | 45.77 |
| day high | 46.36 |
| year high | 47.44 |
| year low | 39.03 |
| market cap | 10204962000 |
| price avg 50 | 44.111 |
| price avg 200 | 43.59545 |
| exchange | NYSE |
| volume | 1032275 |
| avg volume | 846729 |
| open | 46.07 |
| previous close | 45.9 |
| eps | 0.45 |
| pe | 102.22 |
| earnings announcement | 2025-02-05T21:00:00.000+0000 |
| shares outstanding | 221847000 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001015820 | |||
| revenue | 1965311000 | 2141518000 | -8.23 |
| gross profit | 1222924000 | 1384563000 | -11.67 |
| gross profit ratio | 0.62 | 0.65 | -3.76 |
| research and development expenses | 198511000 | 189859000 | 4.56 |
| operating expenses | 777677000 | 808335000 | -3.79 |
| interest income | 78992000 | 32757000 | 141.15 |
| interest expense | 53410000 | 58357000 | -8.48 |
| ebitda | 688555000 | 779355000 | -11.65 |
| ebitdaratio | 0.35 | 0.38 | -8.96 |
| operating income | 445247000 | 531460000 | -16.22 |
| operating income ratio | 0.23 | 0.25 | -8.71 |
| net income | 341303000 | 423211000 | -19.35 |
| net income ratio | 0.17 | 0.2 | -12.12 |
| eps | 1.54 | 1.92 | -19.79 |
Revenue Growth: revenue decreased to 1,965 million in 2023 from 2,142 million in 2022 representing a change of -8.23%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 1,223 million in 2023 from 1,385 million in 2022 representing a change of -11.67%. This indicates a sales profitability decline, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 689 million in 2023 from 779 million in 2022 representing a change of -11.65%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to 445 million in 2023 from 531 million in 2022 representing a change of -16.22%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 341 million in 2023 from 423 million in 2022 representing a change of -19.35%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 1.54 in 2023 from 1.54 in 2022 representing a change of -19.79%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 199 million in 2023 from 190 million in 2022 representing a change of 4.56%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 778 million in 2023 from 808 million in 2022 representing a change of -3.79%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001015820 | |||
| revenue | 501869000 | 496347000 | 1.11 |
| gross profit | 308307000 | 34764000 | 786.86 |
| gross profit ratio | 0.61 | 0.07 | 777.10 |
| research and development expenses | 44453000 | 49103000 | -9.47 |
| operating expenses | 196204000 | 278413000 | -29.53 |
| interest income | 18254000 | 16912000 | 7.94 |
| interest expense | 11484000 | 10922000 | 5.15 |
| ebitda | 177933000 | -159136000 | 211.81 |
| ebitdaratio | 0.35 | -0.32 | 210.58 |
| operating income | 112103000 | -228437000 | 149.07 |
| operating income ratio | 0.22 | -0.46 | 148.53 |
| net income | 98056000 | -183460000 | 153.45 |
| net income ratio | 0.2 | -0.37 | 152.86 |
| eps | 0.44 | -0.83 | 153.01 |
Revenue Growth: revenue increased to 502 million in 2024Q3 from 496 million in 2024Q2 representing a change of 1.11%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 308 million in 2024Q3 from 35 million in 2024Q2 representing a change of 786.86%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 196 million in 2024Q3 from 278 million in 2024Q2 representing a change of -29.53%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 178 million in 2024Q3 from -159 million in 2024Q2 representing a change of 211.81%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 112 million in 2024Q3 from -228 million in 2024Q2 representing a change of 149.07%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 98 million in 2024Q3 from -183 million in 2024Q2 representing a change of 153.45%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.44 in 2024Q3 from 0.44 in 2024Q2 representing a change of 153.01%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 44 million in 2024Q3 from 49 million in 2024Q2 representing a change of -9.47%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001015820 | |||
| total assets | 6115190000 | 6287735000 | -2.74 |
| total liabilities | 2307426000 | 2821124000 | -18.21 |
| total equity | 3807764000 | 3466611000 | 9.84 |
| cash and cash equivalents | 668084000 | 730669000 | -8.57 |
| short term investments | 389698000 | 687597000 | -43.32 |
| long term investments | 29483000 | 23546000 | 25.21 |
| total current assets | 2147560000 | 2393952000 | -10.29 |
| total non current assets | 3967630000 | 3893783000 | 1.90 |
| total current liabilities | 1079293000 | 974523000 | 10.75 |
| total non current liabilities | 1228133000 | 1846601000 | -33.49 |
| common stock | 2702000 | 2702000 | 0.00 |
| retained earnings | 2456800000 | 2160173000 | 13.73 |
| total debt | 1611125000 | 1861450000 | -13.45 |
Total Assets: Total Assets decreased to 6,115 million in 2023 from 6,288 million in 2022 representing a change of -2.74%. Suggesting a decrease in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 668 million in 2023 from 731 million in 2022 representing a change of -8.57%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 390 million in 2023 from 688 million in 2022 representing a change of -43.32%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 2,148 million in 2023 from 2,394 million in 2022 representing a change of -10.29%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 1,079 million in 2023 from 975 million in 2022 representing a change of 10.75%. This indicates a higher short-term debt burden.
Total Liabilities: Total Liabilities decreased to 2,307 million in 2023 from 2,821 million in 2022 representing a change of -18.21%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 3,808 million in 2023 from 3,467 million in 2022 representing a change of 9.84%. This indicates an increase in shareholders' equity.
Retained Earnings: Retained Earnings increased to 2,457 million in 2023 from 2,160 million in 2022 representing a change of 13.73%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 1,611 million in 2023 from 1,861 million in 2022 representing a change of -13.45%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001015820 | |||
| total assets | 6270197000 | 5584640000 | 12.28 |
| total liabilities | 2740203000 | 2179377000 | 25.73 |
| total equity | 3529994000 | 3405263000 | 3.66 |
| cash and cash equivalents | 972985000 | 533644000 | 82.33 |
| short term investments | 507379000 | 356596000 | 42.28 |
| long term investments | 19300000 | 38746000 | -50.19 |
| total current assets | 2454073000 | 1829779000 | 34.12 |
| total non current assets | 3816124000 | 3754861000 | 1.63 |
| total current liabilities | 1128568000 | 1034912000 | 9.05 |
| total non current liabilities | 1611635000 | 1144465000 | 40.82 |
| common stock | 2601000 | 2601000 | 0.00 |
| retained earnings | 2362542000 | 2265463000 | 4.29 |
| total debt | 1919841000 | 1401619000 | 36.97 |
Total Assets: Total Assets increased to 6,270 million in 2024Q3 from 5,585 million in 2024Q2 representing a change of 12.28%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 3,530 million in 2024Q3 from 3,405 million in 2024Q2 representing a change of 3.66%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 973 million in 2024Q3 from 534 million in 2024Q2 representing a change of 82.33%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 507 million in 2024Q3 from 357 million in 2024Q2 representing a change of 42.28%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 2,454 million in 2024Q3 from 1,830 million in 2024Q2 representing a change of 34.12%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 2,363 million in 2024Q3 from 2,265 million in 2024Q2 representing a change of 4.29%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 2,740 million in 2024Q3 from 2,179 million in 2024Q2 representing a change of 25.73%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 1,129 million in 2024Q3 from 1,035 million in 2024Q2 representing a change of 9.05%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 1,920 million in 2024Q3 from 1,402 million in 2024Q2 representing a change of 36.97%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001015820 | |||
| net change in cash | -62585000 | -149847000 | 58.23 |
| operating cash flow | 459455000 | 715264000 | -35.76 |
| free cash flow | 296653000 | 565928000 | -47.58 |
| capital expenditure | -162802000 | -149336000 | -9.02 |
| depreciation and amortization | 205336000 | 208397000 | -1.47 |
| deferred income tax | 10731000 | -9603000 | 211.75 |
| stock based compensation | 47100000 | 49507000 | -4.86 |
| accounts payables | -22417000 | -1756000 | -1176.59 |
| inventory | -44787000 | -61950000 | 27.70 |
| acquisitions net | -149532000 | -63651000 | -134.92 |
| investments in property plant and equipment | -162802000 | -149336000 | -9.02 |
| net cash used for investing activites | -87655000 | -726763000 | 87.94 |
| debt repayment | -436762000 | -108551000 | -302.36 |
| common stock issued | 163000 | 121000 | 34.71 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -433827000 | -125803000 | -244.85 |
| cash at end of period | 668084000 | 730669000 | -8.57 |
| accounts receivables | -55119000 | 15451000 | -456.73 |
| cash at beginning of period | 730669000 | 880516000 | -17.02 |
Net Change in Cash: Net Change in Cash increased to -63 million in 2023 from -150 million in 2022 representing a change of 58.23%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to -163 million in 2023 from -149 million in 2022 representing a change of -9.02%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 47 million in 2023 from 50 million in 2022 representing a change of -4.86%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to -55 million in 2023 from 15 million in 2022 representing a change of -456.73%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to 459 million in 2023 from 715 million in 2022 representing a change of -35.76%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 297 million in 2023 from 566 million in 2022 representing a change of -47.58%. This indicates a decrease in cash generated after accounting for capital expenditures.
Deferred Income Tax: Deferred Income Tax increased to 11 million in 2023 from -10 million in 2022 representing a change of 211.75%. This indicates that the company's tax liability for future periods has increased.
Accounts Payables: The absolute value of Accounts Payables increased to 22 million in 2023 from 2 million in 2022 representing a change of -1176.59%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001015820 | |||
| operating cash flow | 182347000 | 166617000 | 9.44 |
| free cash flow | 138031000 | 127707000 | 8.08 |
| capital expenditure | -44316000 | -38910000 | -13.89 |
| depreciation and amortization | 49993000 | 53393000 | -6.37 |
| deferred income tax | -7670000 | -24260000 | 68.38 |
| stock based compensation | 8850000 | 10112000 | -12.48 |
| accounts receivables | 19364000 | 0 | NaN |
| accounts payables | -3818000 | 1555000 | -345.53 |
| inventory | 12685000 | 70483000 | -82.00 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -43709000 | -38233000 | -14.32 |
| net cash used for investing activites | -231038000 | -17837000 | -1195.27 |
| debt repayment | 496352000 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | -27014000 | 100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 485550000 | -127382000 | 481.18 |
| net change in cash | 439341000 | 19974001 | 2099.56 |
| cash at end of period | 972985000 | 533644000 | 82.33 |
| cash at beginning of period | 533644000 | 513669999 | 3.89 |
Net Change in Cash: Net Change in Cash increased to 439 million in 2024Q3 from 20 million in 2024Q2 representing a change of 2099.56%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 182 million in 2024Q3 from 167 million in 2024Q2 representing a change of 9.44%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 138 million in 2024Q3 from 128 million in 2024Q2 representing a change of 8.08%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -44 million in 2024Q3 from -39 million in 2024Q2 representing a change of -13.89%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 9 million in 2024Q3 from 10 million in 2024Q2 representing a change of -12.48%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Deferred Income Tax: Deferred Income Tax increased to -8 million in 2024Q3 from -24 million in 2024Q2 representing a change of 68.38%. This indicates that the company's tax liability for future periods has increased.
Accounts Payables: The absolute value of Accounts Payables increased to 4 million in 2024Q3 from 2 million in 2024Q2 representing a change of -345.53%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 19 in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 8.88 | 9.7 | -8.46 |
| net income per share | 1.54 | 1.92 | -19.56 |
| operating cash flow per share | 2.08 | 3.24 | -35.92 |
| free cash flow per share | 1.34 | 2.56 | -47.71 |
| cash per share | 4.78 | 6.42 | -25.60 |
| book value per share | 17.21 | 15.7 | 9.57 |
| tangible book value per share | 3.64 | 2.58 | 41.10 |
| shareholders equity per share | 17.21 | 15.7 | 9.57 |
| interest debt per share | 7.52 | 8.7 | -13.51 |
| market cap | 9907671736.6 | 11008785045.5 | -10.00 |
| enterprise value | 10850712736.6 | 12139566045.5 | -10.62 |
| pe ratio | 29.03 | 26.01 | 11.60 |
| price to sales ratio | 5.04 | 5.14 | -1.93 |
| pocfratio | 21.56 | 15.39 | 40.11 |
| pfcf ratio | 33.4 | 19.45 | 71.69 |
| pb ratio | 2.6 | 3.18 | -18.07 |
| ptb ratio | 2.6 | 3.18 | -18.07 |
| ev to sales | 5.52 | 5.67 | -2.60 |
| enterprise value over ebitda | 15.76 | 15.58 | 1.17 |
| ev to operating cash flow | 23.62 | 16.97 | 39.15 |
| ev to free cash flow | 36.58 | 21.45 | 70.52 |
| earnings yield | 0.03 | 0.04 | -10.39 |
| free cash flow yield | 0.03 | 0.05 | -41.76 |
| debt to equity | 0.42 | 0.54 | -21.20 |
| debt to assets | 0.26 | 0.3 | -11.01 |
| net debt to ebitda | 1.37 | 1.45 | -5.61 |
| current ratio | 1.99 | 2.46 | -19.00 |
| interest coverage | 8.34 | 9.11 | -8.46 |
| income quality | 1.35 | 1.69 | -20.35 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.06 | 0.06 | 0.17 |
| research and ddevelopement to revenue | 0.1 | 0.09 | 13.93 |
| intangibles to total assets | 0.49 | 0.46 | 6.55 |
| capex to operating cash flow | 0.35 | 0.21 | 69.71 |
| capex to revenue | 0.08 | 0.07 | 18.79 |
| capex to depreciation | 0.79 | 0.72 | 10.64 |
| stock based compensation to revenue | 0.02 | 0.02 | 3.67 |
| graham number | 24.43 | 26.03 | -6.12 |
| roic | 0.06 | 0.08 | -18.30 |
| return on tangible assets | 0.11 | 0.12 | -12.16 |
| graham net net | -3.0 | -4.41 | 32.01 |
| working capital | 1068267000 | 1419429000 | -24.74 |
| tangible asset value | 805211000 | 569246000 | 41.45 |
| net current asset value | -159866000 | -427172000 | 62.58 |
| invested capital | 4941097000 | 4978964000 | -0.76 |
| average receivables | 424580500 | 401590500 | 5.72 |
| average payables | 91444500 | 99979000 | -8.54 |
| average inventory | 378172500 | 342742500 | 10.34 |
| days sales outstanding | 95.77 | 56.84 | 68.47 |
| days payables outstanding | 41.38 | 47.61 | -13.09 |
| days of inventory on hand | 195.87 | 172.61 | 13.48 |
| receivables turnover | 3.81 | 6.42 | -40.64 |
| payables turnover | 8.82 | 7.67 | 15.07 |
| inventory turnover | 1.86 | 2.11 | -11.88 |
| roe | 0.09 | 0.12 | -26.58 |
| capex per share | 0.74 | 0.68 | 8.75 |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 29.03 on 2023-12-31 from 26.01 on 2022-12-31, representing a change of 11.60%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.42 on 2023-12-31 from 0.54 on 2022-12-31, representing a change of -21.20%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 1.99 on 2023-12-31 from 2.46 on 2022-12-31, representing a change of -19.00%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| QGEN | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 2.26 | 2.24 | 0.96 |
| net income per share | 0.44 | -0.83 | 153.37 |
| operating cash flow per share | 0.82 | 0.75 | 9.28 |
| free cash flow per share | 0.62 | 0.58 | 7.93 |
| cash per share | 6.66 | 4.01 | 66.05 |
| book value per share | 15.88 | 15.34 | 3.51 |
| tangible book value per share | 3.21 | 2.75 | 16.63 |
| shareholders equity per share | 15.88 | 15.34 | 3.51 |
| interest debt per share | 8.69 | 6.36 | 36.53 |
| market cap | 10130848980 | 8930617470 | 13.44 |
| enterprise value | 11077704980 | 9798592470 | 13.05 |
| pe ratio | 25.83 | -12.17 | 312.24 |
| price to sales ratio | 20.19 | 17.99 | 12.19 |
| pocfratio | 55.56 | 53.6 | 3.65 |
| pfcf ratio | 73.4 | 69.93 | 4.95 |
| pb ratio | 2.87 | 2.62 | 9.43 |
| ptb ratio | 2.87 | 2.62 | 9.43 |
| ev to sales | 22.07 | 19.74 | 11.81 |
| enterprise value over ebitda | 62.26 | -61.57 | 201.11 |
| ev to operating cash flow | 60.75 | 58.81 | 3.30 |
| ev to free cash flow | 80.26 | 76.73 | 4.60 |
| earnings yield | 0.01 | -0.02 | 147.12 |
| free cash flow yield | 0.01 | 0.01 | -4.72 |
| debt to equity | 0.54 | 0.41 | 32.13 |
| debt to assets | 0.31 | 0.25 | 22.00 |
| net debt to ebitda | 5.32 | -5.45 | 197.56 |
| current ratio | 2.17 | 1.77 | 22.99 |
| interest coverage | 9.76 | -20.92 | 146.67 |
| income quality | 1.86 | -0.91 | 304.76 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.06 | 0.06 | 1.58 |
| research and ddevelopement to revenue | 0.09 | 0.1 | -10.47 |
| intangibles to total assets | 0.45 | 0.5 | -10.23 |
| capex to operating cash flow | 0.24 | 0.23 | 4.07 |
| capex to revenue | 0.09 | 0.08 | 12.64 |
| capex to depreciation | 0.89 | 0.73 | 21.64 |
| stock based compensation to revenue | 0.02 | 0.02 | -13.44 |
| graham number | 12.55 | 16.89 | -25.67 |
| roic | 0.02 | -0.04 | 144.55 |
| return on tangible assets | 0.03 | -0.07 | 143.18 |
| graham net net | -3.78 | -3.84 | 1.51 |
| working capital | 1325505000 | 794867000 | 66.76 |
| tangible asset value | 712923000 | 610394000 | 16.80 |
| net current asset value | -286130000 | -349598000 | 18.15 |
| invested capital | 4902508000 | 4307501000 | 13.81 |
| average receivables | 357340500 | 363546000 | -1.71 |
| average payables | 77539500 | 75695000 | 2.44 |
| average inventory | 321724500 | 361747500 | -11.06 |
| days sales outstanding | 61.97 | 66.93 | -7.40 |
| days payables outstanding | 36.74 | 14.83 | 147.74 |
| days of inventory on hand | 149.58 | 62.74 | 138.43 |
| receivables turnover | 1.45 | 1.34 | 7.99 |
| payables turnover | 2.45 | 6.07 | -59.63 |
| inventory turnover | 0.6 | 1.43 | -58.06 |
| roe | 0.03 | -0.05 | 151.56 |
| capex per share | 0.2 | 0.18 | 13.73 |
ROE: Return on Equity (ROE) increased to 0.03 on 2024-09-30 Q3 from -0.05 on 2024-06-30 Q2, representing a change of 151.56%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 25.83 on 2024-09-30 Q3 from -12.17 on 2024-06-30 Q2, representing a change of 312.24%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.17 on 2024-09-30 Q3 from 1.77 on 2024-06-30 Q2, representing a change of 22.99%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.54 on 2024-09-30 Q3 from 0.41 on 2024-06-30 Q2, representing a change of 32.13%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Positive Sentiment: Discounted Cash Flow value is 80.38 which is higher than current price 46, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-17 11:41:07
QIAGEN invests heavily in research and development to support internal growth, including the menu expansion of its key platforms.
Sentiment: Positive
Publish Date: 2025-01-16 16:05:00
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repur.
Sentiment: Positive
Publish Date: 2025-01-16 12:41:12
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Genmab A/S Sponsored ADR (GMAB) and Qiagen (QGEN). But which of these two stocks is more attractive to value investors?
Sentiment: Positive
Publish Date: 2025-01-12 13:05:00
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. This new repurchase comes after QIAGEN returned approximately $300 million to shareholders in early 2024 through a synthetic share repurchase. Together, these two programs represent $600 m.
Sentiment: Positive
Publish Date: 2025-01-10 01:30:00
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analyzed from a single biological sample. The new capabilities overcome the assay design challenges of currently available quantitative multiplex PCR methods, making QIAcuity digital PCR ideal for applications such.
Sentiment: Positive
Publish Date: 2025-01-09 16:05:00
GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. This clearance by the U.S. Food and Drug Administration (FDA) marks the second mini syndromic panel in the U.S. and made available for use with QIAstat-Dx systems, supporting QIAGEN's strategy to improve patient treatment options in this important market.
Sentiment: Positive
Publish Date: 2025-01-09 13:15:32
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sentiment: Positive
Publish Date: 2025-01-08 07:56:11
QIAGEN partners with Genomics England to support the United Kingdom's initiative to sequence the genomes of 100,000 newborns with expert-curated genomic content.
Sentiment: Positive
Publish Date: 2025-01-07 16:05:00
REDWOOD CITY, Calif. & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery of the Generation Study. This first-of-its-kind initiative aims to sequence the genomes of 100,000 newborns in England to screen for over 200 selected conditions, enabling earlier diagnosis and treatment of rare conditions. Through its Clinical Knowledge Base, QIAGEN will be the only company to prov.
Sentiment: Positive
Publish Date: 2024-12-30 11:51:10
To support internal growth, QIAGEN is investing heavily in R&D for menu expansion of its key platforms.
Sentiment: Positive
Publish Date: 2024-12-30 10:51:26
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sentiment: Positive
Publish Date: 2024-12-13 10:56:26
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sentiment: Positive
Publish Date: 2024-12-13 09:06:07
QGEN announces the launch of IPA Interpret to extend the analysis capabilities of a human-curated knowledge base with AI technology.
Sentiment: Positive
Publish Date: 2024-12-12 16:05:00
REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, helping researchers understand which genes are involved in a disease, a biological process o.
Sentiment: Positive
Publish Date: 2024-12-09 09:15:34
QGEN achieves milestone with more than 1,000 EZ2 Connect placements worldwide, contributing to a global installed base of over 5,500 EZ series instruments.
Sentiment: Positive
Publish Date: 2024-12-05 16:05:00
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 Connect automated sample preparation instrument, an advancement of the EZ1 instrument line. Launched in 2021, the updated EZ2 Connect has quickly become a market-leading instrument for sample preparation and data management, contributing to a total of more than 5,500 EZ series instruments placed globally. EZ2 Connect.
Sentiment: Positive
Publish Date: 2024-12-05 08:50:45
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
Sentiment: Positive
Publish Date: 2024-11-29 10:40:24
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sentiment: Positive
Publish Date: 2024-11-29 08:41:23
QIAGEN's new Barcelona site is set to drive QIAstat-Dx's growth in infectious diseases and precision medicine testing.
Sentiment: Positive
Publish Date: 2024-11-28 08:45:17
QIAGEN introduces two new customizable dPCR assay design tools featuring advanced design algorithms tailored for diverse microbial applications and custom NGS panels.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
